$HCTI
Healthcare Triangle, Inc. Stock $hcti

$hcti Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024045251 Filed on May 20, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$2.984M	$4.109M	$7.060M
YoY Change	-65.0%	-58.23%	-37.48%
Cost Of Revenue	$2.086M	$3.095M	$5.530M
YoY Change	-68.29%	-62.46%	-41.65%
Gross Profit	$898.0K	$1.070B	$1.530M
YoY Change	-53.88%	67068.86%	-15.66%
Gross Profit Margin	30.09%	26040.4%	21.67%
Selling, General & Admin	$1.535M	$2.059M	$1.602M
YoY Change	-41.81%	-39.24%	-44.66%
% of Gross Profit	170.94%	0.19%	104.71%
Research & Development	$207.0K	$127.0K	$104.0K
YoY Change	102.94%	-76.44%	-96.25%
% of Gross Profit	23.05%	0.01%	6.8%
Depreciation & Amortization	$9.000K	$11.00K	$4.844M
YoY Change	-98.88%	-98.74%	432.31%
% of Gross Profit	1.0%	0.0%	316.6%
Operating Expenses	$2.276M	$2.722M	$6.550M
YoY Change	-35.74%	-43.32%	-0.38%
Operating Profit	-$1.378M	-$1.708M	-$5.020M
YoY Change	-13.61%	-46.77%	5.44%
Interest Expense	-$131.0K	-$149.0K	-$305.0K
YoY Change	-29.57%	-340.32%	267.47%
% of Operating Profit
Other Income/Expense, Net		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Pretax Income	-$1.509M	-$1.857M	-$5.325M
YoY Change	-15.27%	-43.02%	9.79%
Income Tax	$1.000K	$5.000K	$7.000K
% Of Pretax Income
Net Earnings	-$1.510M	-$1.862M	-$5.332M
YoY Change	-15.45%	-43.2%	9.64%
Net Earnings / Revenue	-50.6%	-45.32%	-75.52%
Basic Earnings Per Share	-$0.28	-$0.42
Diluted Earnings Per Share	-$0.28	-$0.42	-$1.26
COMMON SHARES
Basic Shares Outstanding	5.617M shares	4.650M shares	4.278M shares
Diluted Shares Outstanding	5.316M shares	4.455M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.00K	$301.0K	$1.234M
YoY Change	-78.03%	12.73%	-7.98%
Cash & Equivalents	$29.00K	$301.0K	$1.234M
Short-Term Investments
Other Short-Term Assets	$299.0K	$773.0K	$1.259M
YoY Change	-63.36%	16.94%	54.29%
Inventory
Prepaid Expenses
Receivables	$2.005M	$2.095M	$3.236M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.333M	$3.169M	$5.729M
YoY Change	-56.99%	-50.79%	-26.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.00K	$33.00K	$44.00K
YoY Change	-57.89%	-50.75%	-45.0%
Goodwill
YoY Change
Intangibles	$3.301M	$3.637M	$3.611M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.688M	$3.703M	$4.320M
YoY Change	-65.35%	-70.19%	-66.8%
TOTAL ASSETS
Total Short-Term Assets	$2.333M	$3.169M	$5.729M
Total Long-Term Assets	$3.688M	$3.703M	$4.320M
Total Assets	$6.021M	$6.872M	$10.05M
YoY Change	-62.53%	-63.56%	-51.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.937M	$2.013M	$1.953M
YoY Change	109.18%	54.02%	31.87%
Accrued Expenses			$0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.726M	$1.795M	$3.429M
YoY Change	-51.12%	-39.05%	42.16%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.167M	$5.995M	$8.123M
YoY Change	6.51%	-18.21%	32.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$888.0K	$888.0K
YoY Change
Other Long-Term Liabilities	$500.0K	$500.0K	$500.0K
YoY Change	-77.55%	-77.55%	-77.54%
Total Long-Term Liabilities	$500.0K	$1.388M	$1.388M
YoY Change	-77.55%	-37.67%	-37.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.167M	$5.995M	$8.123M
Total Long-Term Liabilities	$500.0K	$1.388M	$1.388M
Total Liabilities	$6.667M	$7.383M	$9.511M
YoY Change	-16.84%	-22.75%	13.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.28M	-$26.77M	-$24.91M
YoY Change	60.37%	68.95%	98.16%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$646.0K	-$511.0K	$538.0K
YoY Change
Total Liabilities & Shareholders Equity	$6.021M	$6.872M	$10.05M
YoY Change	-62.53%	-63.56%	-51.6%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$1.510M	-$1.862M	-$5.332M
YoY Change	-15.45%	-43.2%	9.64%
Depreciation, Depletion And Amortization	$9.000K	$11.00K	$4.844M
YoY Change	-98.88%	-98.74%	432.31%
Cash From Operating Activities	-$935.0K	-$50.00K	$1.214M
YoY Change	-23.42%	-96.88%	-154.49%
INVESTING ACTIVITIES
Capital Expenditures			$6.000K
YoY Change			-57.14%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities			-$6.000K
YoY Change			-57.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	663.0K	-$883.0K	-49.00K
YoY Change	-38.95%	-265.67%	-91.27%
NET CHANGE
Cash From Operating Activities	-935.0K	-$50.00K	1.214M
Cash From Investing Activities			-6.000K
Cash From Financing Activities	663.0K	-$883.0K	-49.00K
Net Change In Cash	-272.0K	-$933.0K	1.159M
YoY Change	101.48%	-13.13%	-141.35%
FREE CASH FLOW
Cash From Operating Activities	-$935.0K	-$50.00K	$1.214M
Capital Expenditures			$6.000K
Free Cash Flow		-$50.00K	$1.208M
YoY Change		-96.89%	-153.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40903
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE TRIANGLE, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3559776
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7901 Stoneridge Drive
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
CY2024Q1	dei	City Area Code CityAreaCode	(925)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	270-4812
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	HCTI
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5616781	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	301000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1234000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2095000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3236000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	773000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1259000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3169000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5729000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3637000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3972000	usd
CY2024Q1	us-gaap	Assets Assets	6872000	usd
CY2023Q4	us-gaap	Assets Assets	10049000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2013000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1953000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1144000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	954000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	1795000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3429000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1043000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1787000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5995000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8123000	usd
CY2024Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	500000	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	500000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	888000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	888000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	7383000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9511000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4726217	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4726217	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4308822	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4308822	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26256000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25443000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26767000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24905000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-511000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	538000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6872000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10049000	usd
CY2024Q1	us-gaap	Revenues Revenues	4109000	usd
CY2023Q1	us-gaap	Revenues Revenues	9838000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	3095000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	8245000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	539000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	883000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1761000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1176000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1628000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	536000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	874000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2722000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4802000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1708000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3209000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	12000	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-149000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-62000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1857000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3259000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1862000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3278000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4455245	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4173286	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	538000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1862000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	787000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-511000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12388000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3278000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	142000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9303000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1862000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3278000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	17000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	335000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	857000	usd
CY2024Q1	hcti	Percentage Of Unallocated Costs PercentageOfUnallocatedCosts	-0.26	pure
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1708000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3209000	usd
CY2024Q1	hcti	Changes In Incomeloss From Operations ChangesInIncomelossFromOperations	1501000	usd
CY2024Q1	hcti	Warrant Liability WarrantLiability	190000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	51000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	36000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	26000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	142000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1141000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-80000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-486000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-155000	usd
CY2024Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-271000	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	276000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	60000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-174000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-744000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	823000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1603000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-883000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	533000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-883000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	533000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-933000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1074000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1234000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1341000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	301000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267000	usd
CY2024Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	787000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	149000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	62000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Treasury Stock ProceedsFromSaleOfTreasuryStock	956000	usd
CY2023Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	5200000	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4420000	usd
CY2023Q4	hcti	Repaid Amount RepaidAmount	1181250	usd
CY2023Q4	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	1181250	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">the standalone selling price for each distinct performance obligation</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify"><span style="font-size: 10pt">the determination of the period of benefit for amortization of deferred costs.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the fair value of assets acquired, and liabilities assumed for business combinations.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation including warrants</span></td> </tr></table>
CY2024Q1	us-gaap	Gross Profit GrossProfit	1070000000.00	usd
CY2024Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1000000000	usd
CY2024Q1	us-gaap	Revenues Revenues	4109000	usd
CY2023Q1	us-gaap	Revenues Revenues	9838000	usd
CY2024Q1	hcti	Changes In Revenue ChangesInRevenue	-5729000	usd
CY2024Q1	hcti	Percentage Of Changes In Revenue PercentageOfChangesInRevenue	-0.58	pure
CY2024Q1	hcti	Segment Operatingloss Profit SegmentOperatinglossProfit	-115000	usd
CY2023Q1	hcti	Segment Operatingloss Profit SegmentOperatinglossProfit	-1046000	usd
CY2024Q1	hcti	Changes In Segment Operatingloss Profit ChangesInSegmentOperatinglossProfit	931000	usd
CY2024Q1	hcti	Percentage Of Changes In Segment Operating Loss Profit PercentageOfChangesInSegmentOperatingLossProfit	-0.89	pure
CY2024Q1	hcti	Unallocated Costsvalue UnallocatedCostsvalue	1593000	usd
CY2023Q1	hcti	Unallocated Costsvalue UnallocatedCostsvalue	2163000	usd
CY2024Q1	hcti	Changes In Unallocated Costs ChangesInUnallocatedCosts	-570000	usd
CY2024Q1	hcti	Percentage Of Incomeloss From Operations PercentageOfIncomelossFromOperations	-0.47	pure
CY2023Q1	us-gaap	Other Income OtherIncome	12000	usd
CY2024Q1	hcti	Changes In Other Income ChangesInOtherIncome	-12000	usd
CY2024Q1	hcti	Percentage Of Other Income PercentageOfOtherIncome	-1	pure
CY2024Q1	us-gaap	Interest Expense InterestExpense	-149000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	-62000	usd
CY2024Q1	hcti	Changes In Interest Expense ChangesInInterestExpense	-87000	usd
CY2024Q1	hcti	Percentage Of Interest Expense PercentageOfInterestExpense	1.40	pure
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1857000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3259000	usd
CY2024Q1	hcti	Changes In Net Incomeloss Before Income Tax Expenses ChangesInNetIncomelossBeforeIncomeTaxExpenses	1402000	usd
CY2024Q1	hcti	Percentage Of Net Incomeloss Before Income Tax Expenses PercentageOfNetIncomelossBeforeIncomeTaxExpenses	-0.43	pure
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1008000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1344000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2095000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3236000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	222	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1285000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3637000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1144000	usd
CY2024Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	500000	usd
CY2024Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	268	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	214	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentrations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the quarter ended March 31, 2024 and 2023 revenue from the top five customers accounted for approximately 70% and 80% of total revenue respectively. For the quarter ended March 31, 2024 and year ended December 31, 2023 accounts receivable from five major customers accounted for approximately 63% and 78% of the total accounts receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $250,000 (valid through March 31, 2024) per institution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024 and December 31, 2023, the Company had $5 and $667 respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	667000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	132000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	132000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	99000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	88000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	11000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	17000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15887000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12250000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3637000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15887000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11915000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3972000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	335000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	857000	usd
CY2024Q1	hcti	Due From Other Related Parties Noncurrents DueFromOtherRelatedPartiesNoncurrents	52000	usd
CY2023Q1	hcti	Due From Other Related Parties Noncurrents DueFromOtherRelatedPartiesNoncurrents	146000	usd
CY2024Q1	hcti	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	33000	usd
CY2023Q1	hcti	Operating Leases Rent Expenses Net OperatingLeasesRentExpensesNet	67000	usd
CY2024Q1	hcti	Unvested Common Stock UnvestedCommonStock	8372	shares
CY2024Q1	hcti	Earnout Payment EarnoutPayment	2500000	usd
CY2024Q1	us-gaap	Goodwill Gross GoodwillGross	1289000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	6018000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	1289000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	970000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	3142000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	11419000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	758000	usd
CY2024Q1	hcti	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Short Term Borrowing BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesShortTermBorrowing	2209000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	679000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3646000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	7773000	usd
CY2024Q1	hcti	Business Combinations Total Purchase Price BusinessCombinationsTotalPurchasePrice	7773000	usd
CY2024Q1	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	362000	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	1112000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	888000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	888000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	1250000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	2000000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3577000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3132000	usd
CY2024Q1	us-gaap	Proceeds From Loans ProceedsFromLoans	750000000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	37500000	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	787500000	usd
CY2024Q1	us-gaap	Shares Issued SharesIssued	417395000	shares
CY2024Q1	us-gaap	Debt Instrument Convertible Liquidation Preference Per Share DebtInstrumentConvertibleLiquidationPreferencePerShare	7.99
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1144000	usd
CY2024Q1	hcti	Prime Rate Plus PrimeRatePlus	0.01	pure
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	1795000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3429000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.50	pure
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3635000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3322000	usd
CY2024Q1	hcti	Deferred Tax Assets Tax Stockbased Compensation Stockbased Compensation DeferredTaxAssetsTaxStockbasedCompensationStockbasedCompensation	7000	usd
CY2023Q4	hcti	Deferred Tax Assets Tax Stockbased Compensation Stockbased Compensation DeferredTaxAssetsTaxStockbasedCompensationStockbasedCompensation	18000	usd
CY2024Q1	hcti	Deferred Tax Assets Warrants DeferredTaxAssetsWarrants	-51000	usd
CY2023Q4	hcti	Deferred Tax Assets Warrants DeferredTaxAssetsWarrants	-172000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3577000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3132000	usd
CY2024Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	usd
CY2023Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	19000	usd
CY2024Q1	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	5000	usd
CY2023Q1	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	19000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	538265	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	17110	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	535375	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.24
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.8
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	3.5
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.59
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	576000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	454000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	120000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1862000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3278000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4455245	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4173286	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4173286	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4455245	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2024Q1	hcti	Stock Issued During Period Value Adjustments StockIssuedDuringPeriodValueAdjustments		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q1	hcti	Stock Issued During Period Value Adjustments StockIssuedDuringPeriodValueAdjustments		usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2024Q1	hcti	Increase In Additional Paidup Capital IncreaseInAdditionalPaidupCapital		usd
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree		usd
CY2024Q1	hcti	Business Combination Recognized Working Capital BusinessCombinationRecognizedWorkingCapital		usd
CY2024Q1	hcti	Warrants Recognized Cost WarrantsRecognizedCost		usd
CY2023Q1	hcti	Warrants Recognized Cost WarrantsRecognizedCost		usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2024Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001839285

Files In Submission

Name	View Source	Status
0001213900-24-045251-index-headers.html	Edgar Link	pending
0001213900-24-045251-index.html	Edgar Link	pending
0001213900-24-045251.txt	Edgar Link	pending
0001213900-24-045251-xbrl.zip	Edgar Link	pending
ea0204678-10q_healthcare.htm	Edgar Link	pending
ea020467801ex31-1_healthcare.htm	Edgar Link	pending
ea020467801ex31-2_healthcare.htm	Edgar Link	pending
ea020467801ex32-1_healthcare.htm	Edgar Link	pending
ea020467801ex32-2_healthcare.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcti-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
hcti-20240331_cal.xml	Edgar Link	unprocessable
hcti-20240331_def.xml	Edgar Link	unprocessable
hcti-20240331_lab.xml	Edgar Link	unprocessable
hcti-20240331_pre.xml	Edgar Link	unprocessable
ea0204678-10q_healthcare_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCTI
Healthcare Triangle, Inc. Stock $hcti

2024 Q2 Form 10-Q Financial Statement

#000121390024045251 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI Healthcare Triangle, Inc. Stock $hcti

2024 Q2 Form 10-Q Financial Statement

#000121390024045251 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI
Healthcare Triangle, Inc. Stock $hcti